Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Forums: Virtual Conferences
Seminar

[TOP] [Previous Slide] [Next Slide]

Dick Swaab and Ahmad Salehi

Slide 2

(View slide in this window or in a new browser window.)

I have mentioned already that I think that cell death is a limited process in Alzheimer's disease and I want to focus your attention on the idea that neuronal inactivity and neuronal atrophy might be a major hallmark of Alzheimer's disease, one so far to which we have paid very little attention. There are many pieces of information in the literature that neuronal inactivity is important. There is a lower total amount of protein in the brains of Alzheimer's patients, there are fewer cytoplasmic and messenger RNA's, glucose metabolism is going down, these events are even preceding the clinical symptoms of Alzheimer's disease. Later glucose metabolism in the brain is related to the cognitive deficiency . It is also noted that in ApoE4 homozygous patients at risk, there is a decreased metabolism although there are no clinical symptoms yet.

Our own work on markers for neuronal inactivity shows a very clear decrease in many areas which are affected. As a marker for neuronal activity in postmortem tissue we found that the size of the Golgi apparatus is a very sensitive one. From animal experiments we know that when a neuron is activated the Golgi apparatus becomes bigger. When you inhibit a neuron the golgi apparatus becomes smaller. The same marker can be used in postmortem tissue using antibodies against certain compounds in the Golgi apparatus. Here you can see the nucleus basalis of Meynert in a control patient and you can see around the nucleus the black staining of the nucleus. The nucleus basalis of Meynert was thought to be an example of an area of tremendous cell death in Alzheimer's disease, which is not the case. It's not a loss of neurons but instead a loss of cholinergic markers. The cells are not recognized as big cholinergic neurons because of shrinkage but they are still present. At the same rate that the number of big neurons is decreasing the number of small neurons in increasing. You can see where you stain for the size of the Golgi apparatus that even those neurons that remain large have small Golgi apparatus in the nucleus basalis of Meynert and the other neurons have only a little bit of Golgi apparatus left. So the inactivity can clearly be seen by staining for the size of the Golgi apparatus.

Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad